nuvation bio is a biopharmaceutical company focused on revolutionizing cancer treatment by discovering, developing and delivering therapies that tackle some of the greatest needs in oncology. nuvation bio’s proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. nuvation bio was founded in 2018 by biopharma industry veteran david hung, m.d., who previously founded medivation, inc., which brought to patients one of the world’s leading prostate cancer medicines. nuvation bio has offices in new york and san francisco.
Company profile
Ticker
NUVB, NUVB-WT
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Panacea Acquisition Corp
SEC CIK
Corporate docs
IRS number
850862255
NUVB stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
18 Apr 24
8-K
Entry into a Material Definitive Agreement
10 Apr 24
8-K
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
25 Mar 24
S-8
Registration of securities for employees
4 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
29 Feb 24
8-K
Departure of Directors or Certain Officers
8 Jan 24
8-K
Departure of Directors or Certain Officers
14 Dec 23
8-K
Departure of Directors or Certain Officers
27 Nov 23
8-K
Departure of Directors or Certain Officers
13 Nov 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 24.40 mm | 24.40 mm | 24.40 mm | 24.40 mm | 24.40 mm | 24.40 mm |
Cash burn (monthly) | 8.56 mm | 9.52 mm | 8.78 mm | 8.61 mm | 5.39 mm | 5.76 mm |
Cash used (since last report) | 56.94 mm | 63.38 mm | 58.42 mm | 57.29 mm | 35.83 mm | 38.34 mm |
Cash remaining | -32.54 mm | -38.98 mm | -34.03 mm | -32.90 mm | -11.44 mm | -13.94 mm |
Runway (months of cash) | -3.8 | -4.1 | -3.9 | -3.8 | -2.1 | -2.4 |
Institutional ownership, Q3 2023
75.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 126 |
Opened positions | 13 |
Closed positions | 12 |
Increased positions | 50 |
Reduced positions | 36 |
13F shares | Current |
---|---|
Total value | 182.94 bn |
Total shares | 165.11 mm |
Total puts | 200.00 |
Total calls | 50.30 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
FMR | 32.68 mm | $43.80 bn |
Omega Fund V | 28.21 mm | $0.00 |
EcoR1 Capital | 19.21 mm | $25.74 bn |
Omega Fund Management | 15.07 mm | $20.20 bn |
BLK Blackrock | 13.21 mm | $17.70 bn |
Deep Track Capital | 7.72 mm | $10.35 bn |
Vanguard | 7.30 mm | $9.78 bn |
Abrams Capital Management | 3.81 mm | $5.11 bn |
Redmile | 3.03 mm | $4.06 bn |
STT State Street | 3.03 mm | $4.06 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Apr 24 | Colleen Sjogren | Stock Option Class A Common Stock | Grant | Acquire A | No | No | 3.23 | 250,000 | 807.50 k | 250,000 |
9 Apr 24 | Colleen Sjogren | Stock Option Class A Common Stock | Grant | Acquire A | No | No | 3.23 | 500,000 | 1.62 mm | 500,000 |
9 Apr 24 | Junyuan Jerry Wang | Class A Common Stock | Grant | Acquire A | Yes | No | 0 | 550,758 | 0.00 | 550,758 |
9 Apr 24 | Junyuan Jerry Wang | Class A Common Stock | Grant | Acquire A | No | No | 0 | 1,378,989 | 0.00 | 1,378,989 |
9 Apr 24 | Junyuan Jerry Wang | Stock Option Class A Common Stock | Grant | Acquire A | No | No | 0.68 | 388,299 | 264.04 k | 388,299 |
9 Apr 24 | Junyuan Jerry Wang | Stock Option Class A Common Stock | Grant | Acquire A | No | No | 0.68 | 486,669 | 330.93 k | 486,669 |
9 Apr 24 | Xiangmin Cui | Class A Common Stock | Grant | Acquire A | Yes | No | 0 | 4,183,002 | 0.00 | 4,183,002 |
9 Apr 24 | Xiangmin Cui | Class A Common Stock | Grant | Acquire A | Yes | No | 0 | 1,675,236 | 0.00 | 1,675,236 |
9 Apr 24 | Xiangmin Cui | Class A Common Stock | Grant | Acquire A | Yes | No | 0 | 314,106 | 0.00 | 314,106 |
News
RBC Capital Maintains Outperform on Nuvation Bio, Raises Price Target to $5
17 Apr 24
ProfoundBio Discovers The Joys Of Having A Wealthy Owner
8 Apr 24
Intel, XPeng And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
3 Apr 24
HC Wainwright & Co. Maintains Buy on Nuvation Bio, Raises Price Target to $8
28 Mar 24
Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
27 Mar 24
Press releases
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
10 Apr 24
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
28 Mar 24
Thinking about buying stock in BigBear.ai, Bitfarms, Paysign, Nuvation Bio, or One Group Hospitality?
27 Mar 24
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
25 Mar 24
Biotech's Role in Addressing the Pancreatic Cancer Emergency
14 Mar 24